Smad proteins transduce signals from TGF-b receptors and regulate transcription of target genes either directly or in combination with other sequence-speci®c transcription factors. AP-1 sites and their cognate transcription factors also play important roles in the gene regulatory activities of TGF-b. In this report, we have investigated the functional interactions of the Smad and AP-1 transcription factors. We demonstrate that Smad and AP-1 complexes speci®cally bind to their cognate ciselements and do not interact with each other on-DNA, whereas o-DNA interactions occur between Smad3 and both c-Jun and JunB. Using both arti®cial constructs speci®c for either the Smad or AP-1 signaling pathways or natural promoters known to be TGF-b-responsive, we have determined that Jun family members downregulate Smad3-mediated gene transactivation whereas AP-1-dependent promoters are synergistically activated by Smad3 and Jun proteins. We propose a model where the presence of Smad-and/or AP-1-speci®c cis-elements within TGF-b-responsive genes allows dynamic modulation of gene expression, in contrast to the existing model where interactions between Smad and AP-1 proteins are merely an on/o mechanism to regulate TGF-b/Smad targets. Oncogene (2001) 20, 3332 ± 3340.
Introduction
Cellular signaling from the TGF-b family of growth factors (e.g. activins, bone morphogenic proteins, and the TGF-bs) is initiated by binding of the ligand to transmembrane receptor serine/threonine kinases, TbRI and TbRII. Following ligand activation, signaling from the receptors to the nucleus occurs predominantly by phosphorylation of cytoplasmic mediators belonging to the Smad family (Piek et al., 1999; MassagueÂ and Chen, 2000; MassagueÂ and Wotton, 2000) . The receptorassociated Smads (R-Smads), such as Smad1, Smad2, Smad3, and Smad5, interact directly with, and are phosphorylated by, activated type I receptors of the TGF-b superfamily. Activation of the R-Smads is ligand-speci®c, but each then forms, upon phosphorylation, heteromeric complexes with Smad4 which functions as a common mediator for all receptor-activated Smad pathways. The R-Smad/Smad4 complexes are then translocated into the nucleus where they may function as transcription factors directly, or in association with other DNA binding factors. Finally, inhibitory Smads, such as Smad6 or Smad7, prevent phosphorylation and/or nuclear translocation of R-Smad/Smad4 heterocomplexes (Piek et al., 1999; MassagueÂ and Chen, 2000; MassagueÂ and Wotton, 2000) .
Thus far, relatively few genuine Smad binding sites have been identi®ed in human gene regulatory sequences. It has been suggested that several genes, such as those encoding the plasminogen activator inhibitor-1 (PAI-1), the a2 chain of type I collagen (COL1A2), or interstitial collagenase (MMP-1), whose TGF-b responsiveness was originally described as AP-1-dependent (Keeton et al., 1991; Chung et al., 1996; Mauviel et al., 1996) , can also be regulated by Smads, via either Smad-speci®c or AP-1 cis-elements (Dennler et al., 1998; Zhang et al., 1998; Chen et al., 1999) .
In this report, we have addressed the issue of potential Smad/AP-1 interactions, both physical or functional, in the context of several TGF-b inducible gene promoter constructs, whose structure allows for precise delineation of the speci®c role played by both Smad and AP-1 pathways in the regulatory eect of TGF-b on gene expression. A predictive model of transcriptional outcome of the interaction, depending on the promoter structure, is proposed.
Results

AP-1 and Smad complexes bind DNA independently: absence of on-DNA interactions
The COL7A1 Smad binding sequence (SBS, Vindevoghel et al., 1998a,b) consists of two adjacent CAGA repeats at the 5' end of the TbRE, and a GCCGGCG stretch in the 3' end (see Figure 1 ), matching the consensus Drosophila Medea binding sequence (Kim et al., 1997) . These two sites, which must be present simultaneously to bind a TGF-b-induced Smad complex (Vindevoghel et al., 1998a) , surround a putative AP-1 binding site, TGAATCA.
First, we sought to determine whether the central AP-1 site was able to bind transcription factors, either alone or in conjunction with the adjacent SBS. Consequently, EMSAs were performed using nuclear extracts from primary cultures of human dermal ®broblasts, under dierent conditions to determine experimental settings most favorable for Smad and AP-1/DNA interactions with the W.T. COL7A1 TbRE probe (see Figure 1) . A 30 min TGF-b stimulation was chosen, corresponding to a time point with maximal Smad translocation (Vindevoghel et al., 1998a) , to maximize the possibility for Smad proteins to interact with AP-1 components. As shown in Figure 2a , binding reactions run in 0.56TBE showed dramatic dierences between nuclear extracts from control and TGF-b-treated ®broblasts. A strong band identi®ed as a Smad3-containing complex (Vindevoghel et al., 1998b) was detected with nuclear extracts from TGFb-treated ®broblasts (lane 2 vs lane 1), and was supershifted with a pan Smad antibody (lane 4). As expected, no Smad complex was present in control extracts (lane 3). When the reaction mixtures were run in 16TAE (right panel), strong binding activity with a migratory pattern similar to that of the Smad complex was observed with both types of nuclear extracts (lanes 5 and 6). Slightly more protein bound the probe in lane 6 as compared to lane 5. Competition assays using 100-fold excess of an 18-mer consensus AP-1 oligonucleo- Figure 1 Nucleotidic sequence and schematic representation of the oligonucleotides used for EMSA. Several oligonucleotides derived from the human COL7A1 promoter TbRE (Vindevoghel et al., 1998a) were used: wild-type (W.T.), mAP-1, DAP-1, mSBS, mut CAGA, and mutMedea. Sequence of the upper strand of the region -500/-444 is shown. Cis-elements of interest (CAGA boxes, AP-1 sites and Medea box) are materialized by boxes and ovals. Inactivating mutations are schematized by crosses. Other oligonucleotides include a 39 bp synthetic oligonucleotide containing three CAGA boxes (36CAGA), known to bind Smad3 and Smad4 (Dennler et al., 1998) , and three distinct oligonucleotides centered on AP-1 sites found in the human COL7A1, MMP-1 and COL1A2 promoters, respectively Figure 2 Lack of natural Smad/Jun heterocomplex formation on either AP-1 or Smad binding sites. Nuclear extracts were prepared from ®broblasts treated (+) or not (7) with TGF-b for 30 min. (a) EMSAs were performed with the labeled W.T. oligonucleotide spanning the region from 7500 to 7444 of the COL7A1 promoter TbRE, using either 0.56Tris-Borate-EDTA (TBE) buer (left panel) or 16TAE (right panel). (b) EMSAs were performed with labeled mAP-1 using 16TAE buer. (c) EMSAs were performed with a labeled mSBS probe, using 16TAE buer. Competition using 100-fold excess of AP-1 oligonucleotide, 5'-CTAGTGATGAGTCAGCCGGATC-3', and supershift assays were carried out as described in Materials and methods. Note that the anti-Sp1 antibody did not aect any of the complexes studied Oncogene Control of gene expression by Smad3/AP-1 interactions F Verrecchia et al tide led to complete disappearance of the complex observed in control extracts (lane 7) while signi®cant binding activity remained in extracts from TGF-btreated ®broblasts (lane 8). The latter complex was supershifted by the pan-Smad antibody (lane 10), indicating that it corresponds to the TGF-b-induced Smad complex identi®ed in lanes 2 and 4, and responsible for the increased DNA binding activity seen in lane 6 vs lane 5. Pan-Fos and pan-Jun antibodies both eliminated all binding activity in control extracts (lanes 11 and 13, respectively) and unveiled the presence of the TGF-b-speci®c Smad complex (lanes 12 and 14, respectively), thereby indicating that the latter does not contain AP-1 components.
These data were con®rmed using the mAP-1 probe, in which the AP-1 site was mutated (Figure 2b ). In that case, only the TGF-b-induced complex bound mAP-1 ( Figure 2b , lane 2), as it was supershifted by the antiSmad antibody (lane 4) but not by pan-Fos or pan-Jun antibodies (lanes 6 and 8). Using mSBS as a probe, (Figure 2c ), identical protein/DNA complexes were observed in extracts from both control and TGF-btreated ®broblasts ( Figure 2c , lane 2 vs lane 1), which were not aected by the pan-Smad antibody (lanes 3 and 4), whereas they were equally supershifted or abolished by both pan-Fos and pan-Jun antibodies (lanes 5 ± 8).
Several conclusions emerge from these experiments. First, the AP-1/DNA complex has a size, as estimated by its gel mobility in non-denaturing conditions, similar to that of the TGF-b-speci®c Smad/DNA complex. Secondly, binding of AP-1 and Smad complexes to the COL7A1 TbRE occurs independently and in an exclusive manner: simultaneous binding of both types of complexes would have resulted in the appearance of an additional`super' complex (Smad/AP-1/DNA) with reduced gel mobility as compared to Smad/DNA or AP-1/DNA complexes. Also, each complex was competed or supershifted independently from the other, further attesting for their independent DNA binding. Thirdly, we did not observe formation of AP-1/Smad heterocomplexes on either Smad-or AP-1-speci®c DNA probes, although it is likely that the respective amounts of AP-1 and Smad proteins, as observed in Figure 2 , would likely be sucient to allow detection of such hypothetical super complexes.
To characterize the speci®c nucleotide requirements for Smad/DNA complex formation in the context of the COL7A1 TbRE, several mutant oligonucleotides were compared for their ability to bind either endogenous Smad complexes or recombinant Smad proteins (Smad3DC and Smad4). As shown in Table 1 , binding of either natural or recombinant Smad proteins to the TbRE was not altered by either a mutation or complete deletion of the AP-1 site (mAP-1 or DAP-1 probes). On the other hand, mSBS, in which both CAGA and Medea boxes have been inactivated simultaneously, did not bind Smad complexes. Interestingly, probes in which the CAGA or Medea boxes were mutated individually revealed dierential nucleotide requirements for endogenous Smad complexes vs recombinant Smad proteins. Speci®cally, neither the mutCAGA nor the mutMedea probe were able to bind natural, TGF-b-induced, Smad complexes, in agreement with our previous demonstration that the Smad binding site within the COL7A1 TbRE is bipartite (Vindevoghel et al., 1998a) . On the other hand, both probes eciently bound recombinant Smad3DC and Smad4.
Smad3 does not form protein/DNA complexes with AP-1 sites
To circumvent a possible quantitative limitation of endogenous Smad3 levels, we examined the capacity of bacterially produced recombinant Smad3, either fulllength or lacking its MH2 domain (Smad3DC), and Smad4 to bind several AP-1-containing EMSA probes. A radiolabeled probe corresponding to the COL7A1 TbRE (Vindevoghel et al., 1998a) was used as a positive control. As shown in Figure 3 , and as expected from previous observations (Vindevoghel et al., 1998b) , Smad3DC eciently bound the COL7A1 TbRE (lane 1). However, it did not interact with any of the AP-1 probes tested (lanes 2 ± 4). Full-length Smad3 neither bound the TbRE-probe (lane 5) nor the AP-1 fragments (lanes 6 ± 8). Smad4 bound the TbRE eciently. Weak binding to two of the three AP-1 probes (lanes 11 and 12) was detected, representing less than 3% of the binding observed with the TbRE (lane 9), as quanti®ed with a phosphorimager.
Next, EMSA experiments were performed, in which binding of in vitro-synthesized Flag-tagged JunB to an AP-1 consensus probe was challenged by the addition of Myc-tagged Smad3. As shown in Figure 4 , addition of Smad3 to the JunB/probe binding reaction led to a signi®cant reduction in JunB/DNA interaction (lane 4 vs lane 2). No Smad3 binding to the AP-1 probe was observed (lane 3). The protein/DNA complex seen in the simultaneous presence of JunB-Flag and Smad3-Myc in the binding reaction was eciently supershifted by an anti-Flag antibody (lane 5) but not with an antiMyc antibody (lane 6). Also, concomitant addition of both antibodies (lane 7) did not result in a supersupershift, as compared to the anti-Flag antibody alone. These data indicate that Smad3 not only does not bind the AP-1 probe, either alone or in the form of a Jun-B/Smad3 complex, but also may prevent Jun binding to its cognate cis-element.
Off-DNA interactions occur between Smad3 and Jun members
To determine the ability of Smad3 and Jun family members to participate in o-DNA protein ± protein interactions, COS-7 cells were transfected with Smad3-Flag and JunB-Myc expression vectors. Forty hours later, the cell lysates were immunoprecipitated with an anti-Myc antibody, and analysed by Western blotting using anti-Myc and anti-Flag antibodies. As shown in Liberati et al., 1999) . The physical interaction between JunB and Smad3 was con®rmed in the mammalian two-hybrid, Gal4-based, transactivation assay, as expression of VP16AD-JunB potently enhanced Gal4-Smad3-mediated transactivation (Figure 5b ), re¯ecting direct JunB/Smad3 interaction. A similar eect was seen when VP16AD-c-Jun was used instead of the JunB vector (not shown). No eect of the empty pVP16AD vector was seen.
Jun overexpression modifies Smad3-mediated transactivation in a promoter-specific fashion
Transactivation of the human COL1A2 promoter by TGF-b, a Smad3-dependent phenomenon (Chen et al., 1999) , is abolished by c-Jun overexpression . PAI-1 promoter activation by TGF-b has been reported to be both AP-1- (Keeton et al., 1991) and Smad-dependent (Dennler et al., 1998; Stroschein et al., 1999) , through distinct TGF-b response elements. In yet other examples, Smad and AP-1 components synergize to activate minimal MMP-1 and c-Jun promoters Wong et al., 1999) . To elucidate the mechanisms underlying this diversity of responses to Smad and AP-1 signals in the context of TGF-b-mediated gene expression, several TGF-b responsive promoter/reporter constructs, (SBE) 4 -Lux, [TRE] 3 -TK/CAT, -524COL7A1/CAT and p800-Lux, were used. First, we examined the transactivation of (SBE) 4 -Lux, an arti®cial Smad3/4-speci®c construct (Zawel et al., 1998) . As anticipated, neither JunB nor c-Jun had any eect on the basal activity of the construct whereas Smad3 overexpression potently induced its activity (Figure 6a ). When co-expressed with Smad3, both cJun and JunB abrogated Smad3-dependent transactivation of (SBE) 4 -Lux.
Smad3/AP-1 interactions were then examined in the context of the AP-1-speci®c arti®cial promoter construct, [TRE] 3 -TK/CAT. c-Jun expression strongly enhanced AP-1 driven-transactivation whereas JunB had a weaker activity (Figure 6b ), consistent with their respective transcriptional properties (Deng and Karin, 1993; Mauviel et al., 1993 Mauviel et al., , 1996 . Smad3 had no eect on the basal activity of the construct, but had a synergistic eect with c-Jun, while slightly potentiating the eect of JunB, to drive AP-1-speci®c transcription.
The transcriptional interactions of Smad3 with Jun family members were then examined in the context of two natural promoters regulated by TGF-b and containing both Smad and AP-1 binding sites, COL7A1 and PAI-1 (Keeton et al., 1991; Dennler et al., 1998; Vindevoghel et al., 1998a) . These promoters showed strikingly dierent responses to Smad/Jun coexpression. Both the -524COL7A1/CAT (Figure 6c) and p800-Lux ( Figure 6d) were strongly induced by Smad3 overexpression (13.5-and 18-fold, respectively). c-Jun alone, and JunB to a lesser extent, exerted a notable stimulatory activity on the COL7A1 promoter (6.5-and 4.5-fold, respectively). In the case of the PAI-1 promoter, c-Jun and JunB alone had a slight stimulatory activity (* twofold). Concomitant expression of c-Jun or JunB together with Smad3 resulted in reduced COL7A1 promoter activity as compared to Smad3 alone (755 and 735%, respectively), whereas in the case of the PAI-1 promoter, c-Jun synergized with Smad3 (*50-fold above control level), and JunB had a slight additive eect.
Inactivation of the SBS converts the COL7A1 promoter from Smad-dependent to AP-1 dependent
We wanted to determine whether genetic manipulation of the COL7A1 TbRE could switch this Smad responsive promoter into an AP-1-dependent one. For this purpose, inactivating mutations, mSBS and mAP-1 (see Figure 1) , were introduced into the COL7A1 TbRE, in the context of the 7524COL7A1/ CAT construct. The transcriptional responses to JunB and Smad3 overexpression were examined. As shown in Figure 7b , mutation of the AP-1 site led to loss of transactivation by JunB alone but JunB still exerted its antagonistic eect against Smad3, as was observed with the wild-type construct (Figure 7a) . Inactivation of the Smad site (Figure 7c ) resulted in the loss of Smad3-driven transactivation. Most importantly, simultaneous expression of Smad3 resulted in potentiation of JunBdriven transactivation, similar to that observed on AP-1-speci®c promoters (see Figure 6b,d) , and opposite to the antagonistic eect of Smad3 and JunB on both the wild-type COL7A1 promoter construct and the arti®cial Smad-speci®c construct (SBE) 4 -Lux (see Figure 6a ,c).
Discussion
Components of the AP-1 transcriptional complex were recognized early as transcriptional targets of TGF-b signaling before the mechanisms of TGF-b signal transduction were known (Pertovaara et al., 1989; Mauviel et al., 1993; Kim et al., 1990) . We now know that Smad3 activation and Jun expression in response to TGF-b occur in a sequential manner. Speci®cally, Smad3/DNA interaction is detectable as early as 10 min after TGF-b addition, persists at least 1 h, and is no longer detectable 3 h post-stimulation (Vindevoghel et al., 1998a) . On the other hand, c-Jun and JunB are induced later, with maximal mRNA levels observed 1 to 6 h after TGF-b addition (Mauviel et al., 1993 . Clearly, Jun expression is a delayed response to TGF-b, and likely depends on the primary Smad cascade, as Smad-speci®c cis-elements are essential for TGF-b-dependent activation of both cJun and JunB promoters (Jonk et al., 1998; .
Control of gene expression by Smad3/AP-1 interactions F Verrecchia et al
The diversity of responses to Smad and AP-1 signals in the context of TGF-b-mediated gene expression led us to determine the functional interactions between Smad3 and Jun proteins. First, we could not detect any on-DNA interactions between Smad and AP-1 proteins, whether on Smad-or AP-1-speci®c elements.
These results are in agreement with a recent study Figure 7 SBS inactivation within the COL7A1 TbRE switches the transcriptional response to Jun/Smad3 interactions from Smadto AP-1-dependent. Fibroblast cultures were transfected with 3 mg of either wild-type 7524COL7A1/CAT (a), or mutant constructs mAP-1COL7A1/CAT and mSBSCOL7A1/CAT (b and c, respectively) promoter/reporter gene constructs, without or with Smad3 and JunB expression vectors. Incubations were continued and promoter activities were determined as described in Figure 6 Oncogene Control of gene expression by Smad3/AP-1 interactions F Verrecchia et al prevent Smad3/DNA complex formation. Thirdly, we have determined that the transcriptional response to Smad3 and Jun is highly dependent on the structure of target promoters, as not only the presence of ciselements, but also their respective position, in¯uences the transcriptional outcome. This is particularly important since the previous reports on Smad/AP-1 interactions used short, so-called minimal, promoter fragments, and have depicted on/o mechanisms that may not be fully representative of the subtle re®ne-ments of gene regulation by TGF-b. In fact, in this report, we provide evidence for dierential nucleotide requirements between endogenous, TGF-b-induced, Smad complexes and recombinant Smad proteins to bind a genuine TbRE (Table 1 ). This is a critical ®nding as binding of recombinant Smads is often used as a test for functionality of a putative TGF-b/Smad response element and our data demonstrate the limitation of such approach.
Context specific transcriptional outcome between Smad3 and Jun members
Several con®gurations of Smad and AP-1 binding sites within promoter/reporter constructs were analysed for their responsiveness to Smad3 and JunB or c-Jun overexpression.
In the context of a Smad-speci®c CAGA repeat (SBE), both c-Jun and JunB inhibit TGF-b/Smad3-induced transcriptional activation (see Figure 6a) . Several possible mechanisms can be suggested to explain this inhibition. The ®rst is that Jun proteins act as direct transcriptional repressors, binding to and blocking transcriptional activation domains intrinsic to Smad3, and preventing its binding to DNA (Figure 4) . Another possible mechanism would be that c-Jun may sequester an essential component, such as CBP/p300, a known transcriptional co-activator for both Smads and Jun proteins (Kamei et al., 1996; Feng et al., 1998; Janknecht et al., 1998) . Because the amount of available p300 is limiting within the nucleus (Kamei et al., 1996; HoÈ ttiger et al., 1998) , secondary induction of high levels of Jun proteins would likely reduce p300/ Smad3 interactions, and related gene transcription. In support of this hypothesis, we have recently shown that p300 overexpression overcomes the inhibition of Smad3-dependent transcription by c-Jun (Verrecchia et al., 2000) . Such mechanism of p300 squelching is also responsible for the antagonistic eects of E1A and RelA on c-Jun-mediated transcription (Lee et al., 1996; Maggirwar et al., 2000) .
In the context of the COL7A1 promoter, which possesses a putative AP-1 site within the TbRE, the lesser inhibition of Smad-dependent transcription by Jun members (Figure 6c ) as compared to that of (SBE) 4 may be explained by some AP-1-dependent maintenance of promoter activity. However, we may conclude that COL7A1 is largely Smad-dependent rather than AP-1 dependent, as its overall behavior in our experimental conditions was remarkably close to that of the arti®cial (SBE) 4 construct. Similarly, we have previously demonstrated that upregulation of the human COL1A2 promoter by TGF-b requires an intact AP-1 binding site within the TbRE , and it has been shown that this promoter may be induced by Smad3/4 overexpression (Chen et al., 1999) but is also blocked by c-Jun overexpression . Remarkably, we have shown that inactivation of the Smad-speci®c binding sites within the COL7A1 TbRE profoundly modi®ed the promoter response, as the antagonistic role of JunB against Smad3-driven transactivation was converted into an additive eect (Figure 7) , as is observed with AP-1-dependent promoters.
In the case of an arti®cial AP-1-dependent promoter, synergistic activation by Smad3 and c-Jun was observed. A similar observation was made in the case of the PAI-1 promoter which exhibits three Smadspeci®c CAGA boxes at positions 7730, 7580, and 7280 (Dennler et al., 1998) distant from functional AP-1 sites at positions 750, 7659 and 670, and 7718 (Keeton et al., 1991) . It should be noted that the c-Jun promoter, which exhibits AP-1 and Smad binding sites separated by *120 bp, is also synergistically activated by Smad3 and c-Jun, without formation of Smad/Jun heterocomplexes on DNA . Their functional cooperation on AP-1-driven transcription likely results from additional, yet unknown, mechanisms, such as, for example, a cooperative recruitment of dierent members of the basal transcription machinery.
Absence of Smad/Jun interactions on DNA
The diversity of responses to Smad and AP-1 signals in the context of TGF-b-mediated gene expression led us to determine the physical interactions between Smad3 and Jun proteins. First, we established that direct binding of either endogenous Smad proteins or recombinant Smad3 proteins to AP-1 binding sequences does not occur. Also, we observed that Smad3 is able to prevent JunB binding to DNA. In addition, no Smad/Jun heterocomplexes were detected in the context of the COL7A1 promoter TbRE. This is in contrast to the data reported by Zhang et al., (1998) who observed direct interaction of Smad3 and Smad4 with c-Jun and c-Fos on DNA. The latter report has recently been questioned (MassagueÂ and Wotton, 2000) , as simultaneous DNA binding of Smad and AP-1 proteins may not be compatible with the threedimensional structure acquired by these factors when bound to DNA (Shi et al., 1998) . Indeed, in agreement with our ®ndings, Wong et al., (1999) demonstrated that no Smad3/c-Jun heterocomplexes were formed despite the synergistic transcriptional eect of these proteins on c-Jun promoter activity. The interaction between Smad3 and JunB occurs via the MH1 domain of Smad3 and a 20 amino acids region close to the leucine zipper portion of JunB Wong et al., 1999) . MH1 is the DNA binding domain of Smad3. The leucine zipper domain is responsible for Jun protein dimerization and subsequent DNA binding. It may therefore be speculated that direct Smad3/ Jun interactions are not compatible with DNA binding of such heterocomplexes, in agreement with our data and with the deductions from the crystal structure of these proteins (Shi et al., 1998) .
The outcome of the Smad3/Jun interaction may depend on the particular Jun family member : implications for a cell-type specific effect Notable dierences were observed between the abilities of JunB and c-Jun to modulate Smad3-driven PAI-1 promoter transactivation. JunB had little eect while cJun strongly synergized with Smad3 to boost PAI-1 promoter activity. These dierences are consistent with their functional properties as transcription factors, since JunB is known to be a rather weak AP-1 transactivator as compared to c-Jun, (Deng and Karin, 1993; Mauviel et al., 1993 Mauviel et al., , 1996 . Interestingly, the regulation of c-Jun and JunB expression by TGF-b is cell-type speci®c : c-Jun is induced only in epithelial cells, whereas JunB expression is strongly enhanced in mesenchymal cells. It is therefore likely that modulation of Smad-mediated transcription by secondary Jun activation is subtly cell-type speci®c.
Under normal conditions, with relatively low levels of AP-1 present in the cell, Smad signaling directly through DNA binding (or cooperatively via interaction with other transcription factors) should predominate. When AP-1 levels are increased, this complex will displace Smad proteins from promoters containing both AP-1 and Smad elements, and will further bind to both Smad complexes and transcriptional co-activators o of the DNA. This will lead to a direct repression of Smad mediated signaling and to an enhancement of AP-1 dominant eects, which will vary depending on the components that are induced. This mechanism might underlie some of the oncogenic potential of AP-1 gene products, as they might be able to directly enhance cellular proliferation through activation of target genes as well as repress TGF-b regulated growth inhibitory signals. For example, v-jun expression has been shown to reverse TGF-b-mediated growth inhibition of chick embryo ®broblasts (Piu et al., 1993) . In summary, our data further re®ne the understanding of the complexity of gene regulation by TGFb. In particular, we have demonstrated that in an identical cellular milieu with identical levels of expression of Smad3 and Jun proteins, transcriptional responses depend on the structure of the target promoter(s), whether they contain AP-1 or Smadspeci®c cis-elements.
Materials and Methods
Cell Cultures
Human dermal ®broblast cultures, established by explanting tissue specimens obtained from neonatal foreskins, were grown in Dulbecco's modi®ed Eagle's medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine, and antibiotics (100 units/ml penicillin, 50 mg/ml streptomycin-G and 0.25 mg/ml Fungizone TM ), and utilized in passages 3 ± 8. Human recombinant TGF-b 1 was a kind gift from R&D Systems Inc.(Minneapolis, MN, USA). It will be referred to as TGF-b throughout the text.
Plasmid Constructs
The human COL7A1 promoter construct, 7524COL7A1/ CAT has been described previously (Vindevoghel et al., 1997) . Mutations within Smad and AP-1 sites were performed by PCR according to standard protocoles (Promega Corp., Madison, WI, USA). (SBE) 4 -Lux which consists of four tandem repeats of the palindromic sequence GTCTAGAC binding Smad3 and Smad4 (Zawel et al., 1998) , p800-Lux which contains 800 bp of human PAI-1 promoter (Keeton et al., 1991) , and [TRE] 3 -TK/CAT, a construct containing three AP-1 binding sites upstream of the thymidine kinase (TK) promoter of herpes simplex virus (Frisch et al., 1990) , were used to delineate Smad/AP-1 interactions in various promoter contexts. N-terminally Flag-tagged Smad3 expression vector and GST-fusion Smad3/4 protein expression vectors have been described previously (Lechleider et al., 1996; de Caestecker et al., 1998) . For c-Jun and JunB, we used full-length human cDNAs in pRSVe expression vector (Chiu et al., 1989) . Constructs were veri®ed by automated sequencing (ABI). Myc-JunB and c-Jun-HA were obtained by subcloning the entire c-Jun and JunB coding sequences into pcDNA3-Myc and pcDNA3-HA (Invitrogen, Groningen, The Netherlands), respectively. VP16AD-JunB was obtained by subcloning the JunB cDNA into the VP16AD expression vector (Clontech, Palo Alto, CA, USA). Gal4-Smad3 has been described previously (Verrecchia et al., 2000) .
Transient cell transfections and reporter assays
Transient cell transfections of human dermal ®broblasts were performed with the calcium phosphate/DNA co-precipitation procedure using a commercial assay kit (Promega). pRSV-bgalactosidase was co-transfected in every experiment to monitor transfection eciencies. CAT activity was measured using [ 14 C]chloramphenicol as substrate (Graham and van der Eb, 1973) , followed by thin layer chromatography and quantitation with a phosphorimager (Amersham-Pharmacia Biotech, Uppsala, Sweden). Luciferase activity was determined with a commercial kit (Promega).
Electrophoresis mobility shift assays
A fragment spanning the region -500/-444 of the COL7A1 promoter, corresponding to the TGF-b response element (TbRE) (Vindevoghel et al., 1998a) , and several oligonucleotides in which either the Smad binding sequence (SBS) or the AP-1 sites were altered, mSBS, mutCAGA, mutMedea, DAP-1 and mAP-1, respectively, were used as probes. A 36CAGA Smad-speci®c probe (Dennler et al., 1998) as well as three distinct AP-1 binding oligonucleotides derived from the human COL7A1, MMP-1 and COL1A2 promoters Mauviel et al., 1996; Vindevoghel et al., 1998a) were also used. A schematic representation and nucleotidic sequence of the dierent oligonucleotides is provided in Figure 1 . Nuclear extracts were isolated using a small scale preparation (Andrews and Faller, 1991) . For supershift experiments, nuclear extracts (5 ± 7 mg) were incubated overnight with antisera prior to the binding reaction. Binding mixtures were separated electrophoretically on native 4% acrylamide gels. Pan-Fos, pan-Jun, and anti-Sp1 antibodies were all from Santa-Cruz Biotechnology (Santa-Cruz, CA, USA). The pan-Smad antibody S367 has been described previously (Lechleider et al., 1996) .
Immunoprecipitations and Western blotting
COS-7 cells were transfected with an activated TbRI expression vector, together with tagged Smad3-Flag and JunB-Myc expression vectors. Forty hours later, cells were solubilized to perform immunoprecipitations and Western analyses using anti-Flag or anti-Myc antibodies (M2 and 9E10, respectively, Sigma), as described previously Verrecchia et al., 2000) .
Recombinant proteins
GST-fusion Smad proteins were expressed in E. coli and puri®ed as directed (Pharmacia). T7 promoter-driven transcription and traduction of tagged Smad and Jun proteins were performed in a single tube assay (TnT 1 , Promega) according to the manufacturer's protocol.
Abbreviations CAT, chloramphenicol acetyl-transferase; EMSA, electrophoretic mobility shift assay; PAI-1, plasminogen activator inhibitor-1; SBE, Smad binding element; SBS, Smad binding sequence (from COL7A1 promoter); TGF-b, transforming growth factor-b; TbRE, TGF-b response element
